The contemporary approach to the care of jehovah's witnesses

Journal of Trauma - Injury, Infection and Critical Care

Volumn 65, Issue 1, 2008, Pages 237-247

  Hughes, Duncan B ^a   Ullery, Brant W ^a   Barie, Philip S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Critical care; Jehovahs Witness; Surgery; Transfusion; Trauma

Indexed keywords

ALBUMIN; ANTIFIBRINOLYTIC AGENT; APROTININ; CYANOCOBALAMIN; DESMOPRESSIN; FOLIC ACID; HEMOGLOBIN; IRON SACCHARATE; OXYGEN; PLACEBO; PLASMA SUBSTITUTE; POLYMERIZED HEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; WARFARIN; HEMATOLOGIC AGENT;

ADULT; BLEEDING; BLOOD AUTOTRANSFUSION; BLOOD CLOTTING DISORDER; BLOOD CONSERVATION; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CHILD HEALTH CARE; CLINICAL TRIAL; COLLOID; CONFIDENTIALITY; CRYSTALLOID; DOCTOR PATIENT RELATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INFORMED CONSENT; INJURY; INTENSIVE CARE; JEHOVAH'S WITNESS; LYMPHOCYTE TRANSFORMATION; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICOLEGAL ASPECT; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PARENT; PATIENT SAFETY; PHLEBOTOMY; PLASMA TRANSFUSION; PRIORITY JOURNAL; REVIEW; SHELF LIFE; SHOCK; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; TRAUMATOLOGY; TREATMENT OUTCOME; TREATMENT REFUSAL; VITAMIN SUPPLEMENTATION;

BLOOD TRANSFUSION; CRITICAL CARE; HEMATOLOGIC AGENTS; HUMANS; JEHOVAH'S WITNESSES; WOUNDS AND INJURIES;

EID: 67649946543     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e318176cc66     Document Type: Review

References (97)

1. Anonymous. Jehovah's Witnesses: Who are They? What do They Believe? New York: Watchtower Bible and Tract Society of New York; 2000.
2. Anonymous. Jehovah's Witnesses. New York: Watchtower Bible and Tract Society of New York; 2006.
3. Anonymous. Should You Believe in the Trinity? New York: Watchtower Bible and Tract Society of New York; 1989.
4. Anonymous. What Does God Require of Us? New York: Watchtower Bible and Tract Society of New York; 1996.
5. Anonymous. 2006 Report of Jehovah's Witnesses Worldwide. New York: Watchtower Bible and Tract Society of New York; 2007.
6. Stark R, Iannacone L. Why the Jehovah's Witnesses grow so rapidly: a theoretical application. J Contemp Relig. 1997;12:133-157.
7. Anonymous. Why True Worship Receives God's Blessing. New York: Watchtower Bible and Tract Society of New York; 1996.
8. Anonymous. Can You Make the World a Better Place? New York: Watchtower Bible and Tract Society of New York; 2001.
9. Anonymous. Salvation Belongs to Jehovah. New York: Watchtower Bible and Tract Society of New York; 2002.
10. Anonymous. Should Christians be Pacifists? New York: Watchtower Bible and Tract Society of New York; 1997.
11. Letsoalo JL. Law, blood transfusions and Jehovah's Witnesses. Med Law. 1998;17:633-638.
12. Anonymous. How Can Blood Save Your Life? New York: Watchtower Bible and Tract Society of New York; 1990.
13. Anonymous. Jehovah's Witnesses and the Question of Blood. New York: Watchtower Bible and Tract Society of New York; 1977.
14. Benson K. Management of the Jehovah's Witness oncology patient: perspective of the transfusion service. Cancer Control. 1995;2:552-556.
15. Singelenberg R. The blood transfusion taboo of Jehovah's Witnesses: origin, development and function of a controversial doctrine. Soc Sci Med. 1990;31:515-523.
16. Anonymous. Statement to the Media. New York: Watchtower Bible and Tract Society of New York; 2000.
17. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev. 2004; 18:105-116.
18. Rogers DM, Crookston KP. The approach to the patient who refuses blood transfusion. Transfusion. 2006;46:1471-1477.
19. Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286:3007-3014.
20. Harris AL. Anesthetic Challenges and the Jehovah's Witness Patient. The Global Textbook of Anesthesiology. Available at: http://gasnet. med.yale.edu/gta.
21. Custody of a minor. In: 375 Mass.; 1978.
22. Prince v Massachusetts. In: 321 US 158; 1944.
23. Jacobson v Massachusetts. In: 197 US 11; 1905.
24. Woolley S. Jehovah's Witnesses in the emergency department: what are their rights? Emerg Med J. 2005;22:869-871.
25. Nelson BS, Heiskell LE, Cemaj S, O'Callaghan TA, Koller CE. Traumatically injured Jehovah's Witnesses: a sixteen-year experience of treatment and transfusion dilemmas at a level I trauma center. J Trauma. 1995;39:681-685.
26. Varela JE, Gomez-Marin O, Fleming LE, Cohn SM. The risk of death for Jehovah's Witnesses after major trauma. J Trauma. 2003; 54:967-972.
27. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am J Med. 1993;94:117-119.
28. Stamou SC, White T, Barnett S, Boyce SW, Corso PJ, Lefrak EA. Comparisons of cardiac surgery outcomes in Jehovah's versus Non-Jehovah's Witnesses. Am J Cardiol. 2006;98:1223-1225.
29. Ott DA, Cooley DA. Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations without blood transfusion. JAMA. 1977; 238:1256-1258.
30. Rosengart TK, Helm RE, DeBois WJ, Garcia N, Krieger KH, Isom OW. Open heart operations without transfusion using a multimodality blood conservation strategy in 50 Jehovah's Witness patients: implications for a bloodless" surgical technique. J Am Coll Surg. 1997;184:618-629.
31. Suess S, Suess O, Brock M. Neurosurgical procedures in Jehovah's Witnesses: an increased risk? Neurosurgery. 2001;49:266-272.
32. Roen PR, Velcek F. Extensive urologic surgery without blood transfusion. N Y State J Med. 1972;72:2524-2527.
33. Bowen JR, Angus PD, Huxster RR, MacEwen GD. Posterior spinal fusion without blood replacement in Jehovah's Witnesses. Clin Orthop Relat Res. 1985:284-288.
34. Nelson CL, Bowen WS. Total hip arthroplasty in Jehovah's Witnesses without blood transfusion. J Bone Joint Surg Am. 1986;68:350-353.
35. Bonakdar MI, Eckhous AW, Bacher BJ, Tabbilos RH, Peisner DB. Major gynecologic and obstetric surgery in Jehovah's Witnesses. Obstet Gynecol. 1982;60:587-590.
36. Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002;288:1499-1507.
37. Kneyber MC, Hersi MI, Twisk JW, Markhorst DG, Plotz FB. Red blood cell transfusion in critically ill children is independently associated with increased mortality. Intensive Care Med. 2007; 33:1414-1422.
38. Margues ATS, Davis JM. The current infectious risks of transfusions. Surg Infect. 2005;6:S23-S31.
39. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42:812-818.
40. Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998; 279:217-221.
41. van Woerkens EC, Trouwborst A, van Lanschot JJ. Profound hemodilution: what is the critical level of hemodilution at which oxygen delivery-dependent oxygen consumption starts in an anesthetized human? Anesth Analg. 1992;75:818-821.
42. 2 × kg(-1) × min(-1). Anesthesiology. 2000;92:407-413.
43. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology. 2000;92:1646-1652.
44. Weiskopf RB, Feiner J, Hopf HW, et al. Oxygen reverses deficits of cognitive function and memory and increased heart rate induced by acute severe isovolemic anemia. Anesthesiology. 2002;96:871-877.
45. Nikolsky E, Mehran R, Aymong ED, et al. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004;94:1023-1027.
46. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004;292:1555-1562.
47. Wu WC, Schifftner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA. 2007;297:2481-2488.
48. Claridge JA, Sawyer RG, Schulman AM, McLemore EC, Young JS. Blood transfusions correlate with infections in trauma patients in a dose-dependent manner. Am Surg. 2002;68:566-572.
49. Hill GE, Frawley WH, Griffith KE, Forestner JE, Mnei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003;54:908-914.
50. Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med. 2006;34:2302-2308.
51. Koch CG, Li L, Van Wagoner DR, Duncan AI, Gillinov AM, Blackstone EH. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg. 2006; 82:1747-1756.
52. Anonymous. Rightly Value Your Gift of Life. The Watchtower; 2004.
53. Anonymous. Be Guided By the Living God. The Watchtower; 2004.
54. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ. 1998;317:235-240.
55. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149-164.
56. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247-2256.
57. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA. 2002;288:2827-2835.
58. Georgopoulos D, Matamis D, Routsi C, et al. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care. 2005;9:R508-R515.
59. Nemoto T, Yokota N, Keane WF, Rabb H.. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001;59:246-251.
60. Elliot JM, Virankabutra T, Jones S, et al. Erythropoietin mimics the acute phase response in critical illness. Crit Care. 2003;7:R35-R40.
61. Pieracci FM, Barie PS. Diagnosis and management of iron-related anemias in critical illness. Crit Care Med. 2006;34:1898-1905.
62. Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med. 2003;31:S651-S657.
63. Price S, Pepper JR, Jaggar SI. Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery. Anesth Analg. 2005;10:325-327.
64. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002;42:114-124.
65. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301-2311.
66. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99:923-930.
67. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175-179.
68. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
69. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-15.
70. Felfernig M. Clinical experience with recombinant activated factor VII in a series of 45 trauma patients. J R Army Med Corps. 2007; 153:32-39.
71. Cameron P, Phillips L, Balogh Z, et al. The use of recombinant activated factor VII in trauma patients: experience from the Australian and New Zealand haemostasis registry. Injury. 2007; 38:1030-1038.
72. Perkins JG, Schreiber MA, Wade CE, Holcomb JB. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma. 2007;62:1095-1099.
73. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005; 352:777-785.
74. Goldberg R, Drummond KJ. Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma. J Clin Neurosci. August 2007; [epub ahead of print].
75. NovoNordisk. Phase III clinical trial: evaluation of recombinant factor viia in patients with severe bleeding due to trauma (NCT00323470). 2006.
76. Squires JE. Artificial blood. Science. 2002;295:1002-1005.
77. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts- blood transfusion. N Engl J Med. 1999;340:438 - 47.
78. Spahn DR, Pasch T. Physiological properties of blood substitutes. News Physiol Sci. 2001;16:38-41.
79. Levy JH, Goodnough LT, Greilich PE, AuBuchon JP. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002;124:35-42.
80. Sprung J, Kindscher JD, Wahr JA, et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg. 2002; 94:799-808.
81. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg. 1998;187:113-120.
82. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg. 2002;195:445-452.
83. Levy JH. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin Biol Ther. 2003;3:509-517.
84. Biopure Corporation. Biopure. 2007. Available at: http:// www.biopure.com. Accessed September 22, 2007.
85. Reid TJ. Hb-based oxygen carriers: are we there yet? Transfusion. 2003;43:280-287.
86. Greenburg AG, Kim HW. Hemoglobin-based oxygen carriers. Crit Care. 2004;8:S61-S64.
87. Messmer K. Hemodilution. Surg Clin North Am. 1975;55:659-678.
88. Bryson GL, Laupacis A, Wells GA. Does acute normovolemic hemodilution reduce perioperative allogeneic transfusion? A meta-analysis. The International Study of Perioperative Transfusion. Anesth Analg. 1998;86:9-15.
89. Monk T. Acute normovolemic hemodilution. Surg Infect. 2005; 6:S9-S15.
90. Baldry C, Backman SB, Metrakos P, Tchervenkov J, Barkun J, Moore A. Liver transplantation in a Jehovah's Witness with ankylosing spondylitis. Can J Anaesth. 2000;47:642-646.
91. Matot I, Scheinin O, Jurim O, Eid A. Effectiveness of acute normovolemic hemodilution to minimize allogeneic blood transfusion in major liver resections. Anesthesiology. 2002;97:794 - 800.
92. Goodnough LT, Monk TG, Brecher ME. Acute normovolemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion. 1998;38:473-476.
93. Corno AF, Laks H, Stevenson LW, Clark S, Drinkwater DC. Heart transplantation in a Jehovah's Witness. J Heart Transplant. 1986; 5:175-177.
94. Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation: staging hepatectomy in a Jehovah's Witness recipient. J Hepatobiliary Pancreat Surg. 2004;11:211-214.
95. Boggi U, Vistoli F, Del Chiaro M, et al. Kidney and pancreas transplants in Jehovah's witnesses: ethical and practical implications. Transplant Proc. 2004;36:601-602.
96. Conte JV, Orens JB. Lung transplantation in a Jehovah's Witness. J Heart Lung Transplant. 1999;18:796-800.
97. Detry O, Deroover A, Delwaide J, et al. Avoiding blood products during liver transplantation. Transplant Proc. 2005;37:2869-2870.